Home Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol
 

Keywords :   


Amgen seeks marketing approval of Repatha (evolocumab) in Japan for treatment of high cholesterol

2015-03-22 06:59:40| Biotech - Topix.net

Amgen today announced that an application seeking marketing approval of RepathaTM for the treatment of high cholesterol has been submitted for review to the Ministry of Health, Labour and Welfare in Japan. Repatha is being developed in Japan by Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas Pharma Inc., a pharmaceutical company headquartered in Tokyo.

Tags: of high japan marketing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.07Hurricane Beryl Graphics
05.07Hurricane Beryl Public Advisory Number 25A
05.07Summary for Hurricane Beryl (AT2/AL022024)
05.07Amazon at 30: What next for 'The Everything Company'?
05.07Atlantic Tropical Weather Outlook
05.07Could the 'flying piano' help transform air cargo?
05.07Eastern North Pacific Tropical Weather Outlook
04.07Hurricane Beryl Graphics
More »